AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03654482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SuperSeton
Description: The SuperSeton will be placed at the outpatient clinic in patients that already have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day care setting instead of a regular seton.
Study NCT00568126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maca Root
Description: 3g/day of Maca Root for 12 weeks.
Study NCT00568126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo provided by research pharmacy daily for 12 weeks.
Study NCT03122314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb_UK) intravenous (IV) was given 100patients
Study NCT03122314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Description: Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
Study NCT01209442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.
Study NCT01209442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.
Study NCT01209442 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT (Radiation Therapy)
Description: Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx)
Study NCT01256112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Supported Behavioral Intervention
Description: Parents of participants receive training in behavioral support at home in order to facilitate lifestyle change associated with dietary choices and physical activity designed to produce gradual weight loss.
Study NCT01256112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition/Activity Education (NAE)
Study NCT01256112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition/Activity Education (NAE)
Study NCT00405548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNP (nesiritide)
Study NCT00405548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03247166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPS™ System
Description: The TOPS™ System is an alternative to spinal fusion that is designed to stabilize but not fuse the effected vertebrai level to alleviate pain stemming from degenerative joints
Study NCT01709695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine Hydrochloride XR
Description: Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
Study NCT01709695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
Study NCT03072485 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: Topical sirolimus applied to the skin
Study NCT03072485 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Topical metformin applied to the skin
Study NCT03072485 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diclofenac
Description: Topical diclofenac applied to the skin
Study NCT00546611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEP005
Study NCT00581568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cutaneous Effects of Cryogen Spray Cooling
Description: Cutaneous Effects of Cryogen Spray Cooling
Study NCT04505566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.45% ophthalmic solution
Description: Ketorolac 0.45% ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
Study NCT04505566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Preservative-free artificial tears
Description: Preservative free artificial tears ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
Study NCT04505566 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aqueous PGE2 and inflammatory cytokines measurements
Description: After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured
Study NCT04505566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqueous PGE2 and inflammatory cytokines measurements
Description: After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured
Study NCT04505566 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aqueous PGE2 and inflammatory cytokines measurements
Description: After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured
Study NCT01398046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: dasatinib (100mg) PO x1
Study NCT01398046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib plus Rabeprazole
Description: Rabeprazole (20mg) PO twice daily (Days 1-3); Dasatinib (100mg) PO x1 (Day 4)
Study NCT01398046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib plus Rabeprazole AND Betaine Hydrochloride
Description: Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Dasatinib (100mg) PO x1 on Day 4
Study NCT02428439 — intervention group
Intervention type: DRUG
Intervention: bupropion or lamotrigine
Description: Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.
Study NCT03228797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: an ultrasound guided rectus sheath block
Study NCT03228797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: multiholed catheter
Description: gauge multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer at 3 to 5 cm away from the lower end of the surgical incision
Study NCT03228797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: an ultrasound guided rectus sheath block &multiholed catheter
Description: a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
Study NCT01822717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonvisual foot inspection
Description: Teaching use of nonvisual senses (tactile and olfactory) to empower people with diabetes and visual impairment to perform a systematic self-examination of their own feet
Study NCT01822717 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard instructions for foot care for people with visual impairment include advice to have a sighted family member or friend check the person's feet regularly
Study NCT02856555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firsocostat
Description: Capsules orally once daily.
Study NCT02856555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to firsocostat orally once daily.
Study NCT03424356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide
Description: 0.15 mg/kg rocuronium bromide
Study NCT03424356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Description: 1-2 ml saline solution
Study NCT03424356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 1mcg/kg for induction
Study NCT02634593 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low glycemic load snacks
Description: Intervention to replace standard night-time food and drinks with lower glycemic load options
Study NCT02173457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar
Description: Take orally
Study NCT02173457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Take orally
Study NCT01742585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral
Study NCT01742585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study NCT02699619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pinloc
Description: 3 hook pins interlocked in plate.
Study NCT02699619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2 Hansson pins
Description: 2 isolated hook pins.(Without plate)
Study NCT00882856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Bisoprolol Vitabalnas 10 mg once daily
Study NCT00882856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03424356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 1mcg/kg for induction
Study NCT03424356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 2-3mg/kg for anaesthetic induction
Study NCT03424356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2-3mg/kg for anaesthetic induction
Study NCT03424356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cystoscopy
Description: patients will treated with this surgical procedure
Study NCT03424356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cystoscopy
Description: patients will treated with this surgical procedure
Study NCT01387464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-303
Description: 0.075% bromfenac in DuraSite dosed QD
Study NCT01387464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromday™
Description: 0.09% bromfenac dosed QD
Study NCT01858740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
Study NCT01858740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01858740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01858740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT01858740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
Study NCT03780634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
Study NCT03780634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HAIC
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
Study NCT01858740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T Cell-Depleted Hematopoietic Stem Cell Transplantation
Description: Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
Study NCT01858740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT01858740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT01858740 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT03400163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: BMS-986036 20 mg QD
Study NCT03400163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD
Study NCT02241343 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Venous occlusion (leg tourniquet, made in-house)
Description: Leg occlusion applied via a blood pressure cuff. Venous occlusion checked using duplex ultrasound
Study NCT02997059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 200 mg/ day
Study NCT03780634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 200mg intravenously every 3 weeks
Study NCT03780634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 mg Bid Po
Study NCT01212809 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm Ultra
Description: Split-face injection of Juvéderm Ultra into vertical lip rhytids and radial cheek lines on one side of face
Study NCT02997059 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00729963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (\< 1.8 kg) over the first month of treatment.
Study NCT00729963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Study NCT00753454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Liquid certolizumab pegol administered every two weeks as a single injection (400 mg at Entry, Week 2 \& Week 4, followed by 200 mg every 2 weeks).
Study NCT00134563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration
Study NCT00134563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for teriflunomide)
Description: Film-coated tablet~Oral administration
Study NCT03736122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSG-001
Description: BSG-001 is in solution form, 4mg per vial (2mg/mL) with Inhalation as route of administration using nebulizer.~BSG-001 will be administrated as an approximately 5 - 30 minutes inhalation session daily for 3 cycles (in repeated 28 days cycle).
Study NCT04264949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education in the use of smartphone app (Mon coach dos)
Description: In addition to conventional care and the therapeutic education program, GA will benefit from three education sessions (one per week) on the use of the smartphone app mon coach dos
Study NCT04264949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional care
Description: conventional care and the therapeutic education program
Study NCT04264949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional care
Description: conventional care and the therapeutic education program
Study NCT01161173 — intervention group
Intervention type: DRUG
Intervention: Erlotinib
Description: Erlotinib was provided in the retail versions of the product.
Study NCT03017131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC
Study NCT03017131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03017131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT03017131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically Engineered NY-ESO-1-specific T Lymphocytes
Description: Given IV and IP
Study NCT03017131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03219372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin Pill
Description: statin
Study NCT03219372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo
Study NCT05497570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenoxicam Injectable Product
Description: After arthrocentesis procedure, 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint
Study NCT02086240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XBD173
Description: XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.
Study NCT04124445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Radiofrequency Ablation
Description: Radiofrequency ablation, also called rhizotomy, is a nonsurgical, minimally invasive procedure that uses heat to reduce or stop the transmission of pain. Radiofrequency waves ablate, or burn, the nerve that is causing the pain, essentially eliminating the transmission of pain signals to the brain.
Study NCT02740192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Post-op adductor canal block using Bupivacaine
Study NCT02740192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periarticular Injection
Description: Intra-op periarticular injection of Ropivacaine
Study NCT02740192 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Periarticular Injection
Description: Intra-op periarticular injection of Ropivacaine
Study NCT02740192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine was used for the periarticular injection
Study NCT04664933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of neuroprotective agents
Description: Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min
Study NCT02518867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity iTBS
Description: In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (high intensity , 100% of active motor threshold) TBS for 3 days.
Study NCT02518867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low intensity iTBS
Description: In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low intensity, 80% of active motor threshold) TBS for 3 days.
Study NCT02518867 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham iTBS
Description: In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment.
Study NCT02985996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.
Study NCT02985996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya
Description: Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
Study NCT04516798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration
Description: local and whole-body vibration were applied
Study NCT02740192 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine was used for the periarticular injection
Study NCT02740192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine was used for the periarticular injection
Study NCT01027702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of donor lymphocytes
Description: A donor lymphocyte infusion will be given to provide T cells. There will be a dose escalation: 3 x 10\^4, 4 x 10\^4, 5 x 10\^4, 6 X 10\^4, 8 x 10\^4, and 10 X10\^4 cells/kg body weight. At least three patients will be assessed at each dose to determine safety before dose is increased.
Study NCT02155023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin dosing
Study NCT02155023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose sensors IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)